Browsing by Author "0099498"
Now showing items 1-20 of 90
-
A Computer Simulation Model of Pharmaceutical Innovation
(Pharmaceutical Economics: Papers Presented at the 6. Arne Ryde Symposium, Helsingborg, Sweden 1982, 1984) -
A Computer Simulation Model of Pharmaceutical Innovation
(Pharmaceutical Economics, 1984) -
A New Look at the Returns and Risks to Pharmaceutical R & D
(Management Science, 1990-07) -
A New Look at the Returns and Risks to Pharmaceutical R&D
(1990-07)This study investigates the returns to R&D for 100 new drugs introduced into the United States during the decade of the 1970s. In contrast to prior studies, it incorporates several significant structural changes that have ... -
AN ANALYSIS OF UNITED-STATES INTERNATIONAL COMPETITIVENESS IN PHARMACEUTICALS
(MANAGERIAL AND DECISION ECONOMICS, 1989) -
An Economic Analysis of Global Policy Proposals to Prohibit Compensation of Blood Plasma Donors
(International Journal of the Economics of Business, 2016-05-03)© 2016 International Journal of the Economics of Business.Human blood plasma and its derivative therapies have been used therapeutically for more than 50 years, after first being widely used to treat injuries during World ... -
Are the Economics of Pharmaceutical R&D Changing? Productivity, Patents and Political Pressures
(PharmacoEconomics, 2004)Pharmaceutical R&D competition in the 1980s and 1990s was characterized by rising R&D expenditures, favorable returns to innovators, and the introduction of many new classes of drugs with high social benefits. However in ... -
Biosimilar competition: lessons from Europe
(Nature Reviews Drug Discovery, 2014-01-21) -
Brand Loyalty, Entry, and Price Competition in Pharmaceuticals after the 1984 Drug Act
(1992-10)IN 1984, Congress enacted a new law that greatly affected the economics of the pharmaceutical industry in the United States. It has been characterized as the most important legislation affecting competition in the pharmaceutical ... -
Competition between Generic and Branded Drugs
(Pharmaceutical innovation: incentives, competition, and cost-benefit analysis in international perspective, 2007-04-30)The pharmaceutical industry worldwide is a rapidly burgeoning industry contributing to growth of gross domestic product and employment. Technological change in this field has been very rapid, with many new products being ... -
Cost of innovation in the pharmaceutical industry.
(J Health Econ, 1991-07)The research and development costs of 93 randomly selected new chemical entities (NCEs) were obtained from a survey of 12 U.S.-owned pharmaceutical firms. These data were used to estimate the pre-tax average cost of new ... -
Data Exclusivity for Biologics
(Nature Reviews Drug Discovery, 2011-01) -
Demand Shifting, Optimal Firm Growth, and Rule-of-Thumb Decision Making
(Quarterly Journal of Econoics, 1970-05) -
Determinants and Distributional Aspects of Enrollment in U.S. Higher Education
(Journal of Human Resources, 1972-12) -
Developing drugs for developing countries.
(Health Aff (Millwood), 2006-03)Infectious and parasitic diseases create enormous health burdens, but because most of the people suffering from these diseases are poor, little is invested in developing treatments. We propose that developers of treatments ... -
Do Faster FDA Drug Reviews Adversely Affect Patient Safety? An Analysis of the 1992 Prescription Drug User Fee Act
(2008)times have significantly declined since the passage of PDUFA in 1992, while agency resources have expanded through user fees. After the recent withdrawal of Vioxx and other high-profile products, there have been increasing ... -
Do faster food and drug administration drug reviews adversely affect patient safety? An analysis of the 1992 prescription drug user fee act
(Journal of Law and Economics, 2008-05-01)Food and Drug Administration (FDA) review times have significantly declined under the user-fee regime. This situation has provoked concerns that drug safety has been adversely affected. Combining information from several ... -
Does generic entry always increase consumer welfare?
(Food Drug Law J, 2012)This article examines how the nature of competition between brands in a therapeutic category changes after generic entry and provide a framework for analyzing the effect of generic entry on consumer welfare that takes into ... -
Economic Evaluation of Drug Treatment for Psychiatric Disorders: The New Clinical Trial Protocol
(Psychopharmacology: the Fourth Generation of Progress, 1995) -
Economic return of clinical trials performed under the pediatric exclusivity program.
(JAMA, 2007-02-07)CONTEXT: In 1997, Congress authorized the US Food and Drug Administration (FDA) to grant 6-month extensions of marketing rights through the Pediatric Exclusivity Program if industry sponsors complete FDA-requested pediatric ...
